Aquestive Therapeutics AQST
$3.46 −$0.25 (-6.61%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.52 +1.73%
Open$3.62
Prev close$3.71
Day range$3.41 – $3.65
Volume3.36M
Market cap$434.88M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$7.56M-41.0% YoY
Operating profit-$14.47M-26.0% YoY
Net profit-$16.50M-6.8% YoY
Diluted EPS-$0.13+7.1% YoY
Free cash flow-$7.63M+40.8% YoY
Operating cash flow-$7.05M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
Return on assets-56.0%
Current ratio6.12
Liabilities / assets159.4%
Cash & investments$90.35M
Total debt$58.15M
Net cash (debt)$32.20M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $7.56M | $13.82M | $14.45M | $44.55M | $13.02M |
| Total Operating Revenue | $7.56M | $13.82M | $14.45M | $44.55M | $13.02M |
| Cost of Revenue | $3.61M | $4.02M | $3.47M | $18.56M | $5.84M |
| Gross Profit | $3.95M | $9.80M | $10.98M | $25.99M | $7.18M |
| Operating Expense | $18.42M | $18.03M | $15.18M | $97.04M | $36.02M |
| Selling and Admin Expenses | $14.17M | $14.06M | $10.98M | $79.85M | $32.82M |
| Research & Development | $4.25M | $3.96M | $4.20M | $17.19M | $3.20M |
| Operating Profit | -$14.47M | -$8.22M | -$4.20M | -$71.05M | -$28.84M |
| Net Non-Operating Interest Income (Expense) | -$2.03M | -$2.96M | -$3.85M | -$12.73M | -$3.02M |
| Non-Operating Interest Income | $853,000.00 | $882,000.00 | $83,000.00 | $4.37M | $1.25M |
| Non-Operating Interest Expense | $2.88M | $3.84M | $3.94M | $17.10M | $4.27M |
| Special Income (Charges) | $0.00 | -$11.68M | – | – | – |
| Pretax Profit | -$16.50M | -$22.86M | -$8.06M | -$83.78M | -$31.86M |
| Net Profit | -$16.50M | -$22.86M | -$8.06M | -$83.78M | -$31.86M |
| Profit from Continuing Operations | -$16.50M | -$22.86M | -$8.06M | -$83.78M | -$31.86M |
| Net Income to Parent Company | -$16.50M | -$22.86M | -$8.06M | -$83.78M | -$31.86M |
| Net Income to Common Stockholders | -$16.50M | -$22.86M | -$8.06M | -$83.78M | -$31.86M |
| Basic EPS | -$0.13 | -$0.18 | -$0.07 | -$0.78 | -$0.26 |
| Diluted EPS | -$0.13 | -$0.18 | -$0.07 | -$0.78 | -$0.26 |
| Other Income (Expense) | – | -$11.68M | – | – | – |
| -Less:Other Special Charges | – | $11.68M | – | – | – |
| Tax | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $119.33M | $132.10M | $141.13M | $160.43M | $160.43M |
| Total Current Assets | $105.83M | $118.49M | $130.18M | $149.27M | $149.27M |
| Cash and Cash Equivalents & Short-Term Investments | $90.35M | $98.49M | $110.73M | $121.17M | $121.17M |
| -Cash and Cash Equivalents | $90.35M | $98.49M | $110.73M | $121.17M | $121.17M |
| Receivables | $5.25M | $9.33M | $6.87M | $17.76M | $17.76M |
| -Accounts Receivable | $3.70M | $7.72M | $5.26M | $8.01M | $8.01M |
| -Other Receivables | $1.55M | $1.61M | $1.61M | $10.33M | $10.33M |
| -Receivables Adjustments Allowances | $0.00 | $0.00 | $0.00 | -$582,000.00 | -$582,000.00 |
| Inventory | $7.31M | $7.37M | $8.07M | $6.17M | $6.17M |
| Other Current Assets | $2.91M | $3.31M | $4.52M | $4.17M | $4.17M |
| Total Non-Current Assets | $13.50M | $13.61M | $10.94M | $11.16M | $11.16M |
| Net PPE | $11.81M | $11.91M | $8.31M | $8.51M | $8.51M |
| -Gross PPE | $51.33M | $56.17M | $52.43M | $52.54M | $52.54M |
| -Accumulated Depreciation | -$39.52M | -$44.26M | -$44.13M | -$44.02M | -$44.02M |
| Non Current Accounts Receivables | $1.00M | $1.00M | $2.00M | $2.00M | $2.00M |
| Other Non-Current Assets | $693,000.00 | $701,000.00 | $635,000.00 | $642,000.00 | $642,000.00 |
| Total Liabilities | $190.15M | $188.69M | $175.18M | $194.09M | $194.09M |
| Total Current Liabilities | $17.30M | $16.48M | $31.75M | $47.61M | $47.61M |
| Payables | $9.22M | $9.29M | $12.30M | $30.21M | $30.21M |
| -Accounts Payable | $8.82M | $8.97M | $11.89M | $29.86M | $29.86M |
| -Total Tax Payable | $404,000.00 | $328,000.00 | $408,000.00 | $349,000.00 | $349,000.00 |
| Current Accrued Expenses | $988,000.00 | $968,000.00 | $972,000.00 | $973,000.00 | $973,000.00 |
| Short-Term Debt and Capital Lease Obligation | $656,000.00 | $852,000.00 | $14.32M | $10.63M | $10.63M |
| -Current Debt | $33,000.00 | $32,000.00 | $13.66M | $9.99M | $9.99M |
| -Current Capital Lease Obligation | $623,000.00 | $820,000.00 | $662,000.00 | $631,000.00 | $631,000.00 |
| Current Deferred Liabilities | $1.09M | $1.09M | $1.09M | $1.09M | $1.09M |
| Other Current Liabilities | $1.16M | $1.05M | $1.00M | $1.00M | $1.00M |
| Total Non-Current Liabilities | $172.85M | $172.21M | $143.43M | $146.48M | $146.48M |
| Long Term Debt and Capital Lease Obligation | $58.12M | $58.18M | $29.26M | $31.86M | $31.86M |
| -Long Term Debt | $50.76M | $50.65M | $25.10M | $27.52M | $27.52M |
| -Long Term Capital Lease Obligation | $7.36M | $7.53M | $4.16M | $4.34M | $4.34M |
| Non-Current Deferred Liabilities | $18.57M | $18.85M | $19.12M | $19.39M | $19.39M |
| Other Non-Current Liabilities | $34.97M | $34.02M | $32.97M | $33.21M | $33.21M |
| Total Equity | -$70.82M | -$56.59M | -$34.05M | -$33.66M | -$33.66M |
| Stockholders' Equity | -$70.82M | -$56.59M | -$34.05M | -$33.66M | -$33.66M |
| Capital Stock | $126,000.00 | $126,000.00 | $124,000.00 | $122,000.00 | $122,000.00 |
| -Common Stock | $126,000.00 | $126,000.00 | $124,000.00 | $122,000.00 | $122,000.00 |
| Additional Paid-In Capital | $423.47M | $421.21M | $420.88M | $413.21M | $413.21M |
| Retained Earnings | -$494.42M | -$477.92M | -$455.06M | -$447.00M | -$447.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$7.05M | -$9.44M | -$14.81M | -$52.43M | -$8.47M |
| Net cash flow from continuing operations | -$7.05M | -$9.44M | -$14.81M | -$52.43M | -$8.47M |
| Net Income from Continuing Operations | -$16.50M | -$22.86M | -$8.06M | -$83.78M | -$31.86M |
| Gain/Loss from Continuing Operations | $0.00 | – | – | – | – |
| Depreciation & Depletion & Amortization | $156,000.00 | $136,000.00 | $113,000.00 | $548,000.00 | $130,000.00 |
| Other Non-Cash Items | $1.46M | $1.81M | $3.21M | $11.00M | $2.75M |
| Change in Working Capital | $5.71M | -$3.10M | -$12.39M | $12.18M | $19.14M |
| -Change in Receivables | $4.07M | -$2.46M | $10.90M | -$10.37M | -$5.96M |
| -Change in Inventory | $50,000.00 | $706,000.00 | -$1.90M | -$126,000.00 | $1.71M |
| -Change in Prepaid Assets | $408,000.00 | $2.14M | -$340,000.00 | $698,000.00 | -$685,000.00 |
| -Change in Payables and Accrued Expense | $1.46M | -$3.21M | -$20.78M | $22.56M | $24.34M |
| -Change In Other Working Capital | -$272,000.00 | -$273,000.00 | -$272,000.00 | -$571,000.00 | -$272,000.00 |
| Net cash flow from investing | -$584,000.00 | -$212,000.00 | -$52,000.00 | -$562,000.00 | -$85,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$584,000.00 | -$212,000.00 | -$52,000.00 | -$562,000.00 | -$85,000.00 |
| Capital Expenditure | -$584,000.00 | -$212,000.00 | -$52,000.00 | -$562,000.00 | -$85,000.00 |
| Financing Cash Flow | -$511,000.00 | -$2.59M | $4.42M | $102.62M | $660,000.00 |
| Net Cash Flow from Continuing Financing Activities | -$511,000.00 | -$2.59M | $4.42M | $102.62M | $660,000.00 |
| Net Issuance Payments Of Debt | -$10,000.00 | $5.44M | -$8,000.00 | -$26,000.00 | $6,000.00 |
| Net Common Stock Issuance | -$27,000.00 | -$79,000.00 | $4.76M | $100.65M | -$301,000.00 |
| Proceeds from Stock Option Exercised | $177,000.00 | $759,000.00 | $1,000.00 | $2.81M | $984,000.00 |
| Net Other Financing Charges | -$651,000.00 | -$8.71M | -$329,000.00 | -$821,000.00 | -$29,000.00 |
| Ending Cash Balance | $90.35M | $98.49M | $110.73M | $121.17M | $121.17M |
| Net Change in Cash | -$8.14M | -$12.24M | -$10.44M | $49.62M | -$7.89M |
| Beginning Cash Balance | $98.49M | $110.73M | $121.17M | $71.55M | $129.06M |
| Free Cash Flow | -$7.63M | -$9.65M | -$14.86M | -$52.99M | -$8.55M |
No comments yet — be the first to weigh in on AQST.
Sign in to join the discussion.